History of preterm birth: QUiPP personalized risk stratification

Quick take: If you’ve had a preterm birth before, the QUiPP (Quantitative Individual Prediction of Preterm birth) app can turn your past obstetric history, cervical measurements, and fetal‑fibronectin results into a personalized risk number. A higher QUiPP score means a greater chance of delivering before 37 weeks, and your care team can use that information to decide on closer monitoring, preventative medication, or timely delivery.

It’s 2 a.m., you’re scrolling through the night‑mode of your phone, heart racing after a sudden cramp, and a pop‑up reminds you of the baby who arrived three months early last pregnancy. You wonder: “Will this happen again? Is there a way to know?” You’re not alone. Many parents who have experienced a preterm birth ask the same question, and the answer is increasingly rooted in data, not guesswork. The QUiPP app—short for Quantitative Individual Prediction of Preterm birth—offers a personalized risk stratification that pulls together the pieces of your obstetric history, the length of your cervix, and a quick lab test called fetal‑fibronectin (fFN). In this guide we’ll walk through how the tool works, what the numbers mean, and how clinicians turn those numbers into actions that can keep your next baby closer to term.

We’ll cover the science behind the algorithm, the practical steps of using the app, the evidence that backs its predictions, and the limitations you should keep in mind. By the end of the article you’ll know whether QUiPP is right for you, how to interpret a score, and what questions to ask at your next prenatal visit. If you’re ready to calculate your own numbers, you can try the QUiPP Preterm Birth Risk calculator below the article.

What is the QUiPP app and why it matters for women with a history of preterm birth

The QUiPP app is a digital decision‑support tool created by researchers at the University of Manchester and the National Health Service (NHS) in the United Kingdom. Its purpose is simple: combine objective clinical data—cervical length measured by transvaginal ultrasound, the presence of fetal‑fibronectin in vaginal fluid, and key elements of your pregnancy history—into a single probability that you will deliver before 37 weeks. The tool is designed for use in the second trimester, typically between 16 and 28 weeks, when the risk of a recurrent preterm birth can be most accurately assessed.

Why does a prior preterm birth matter? A history of delivering before 37 weeks is the strongest single predictor of a subsequent preterm delivery. Studies from ACOG (American College of Obstetricians and Gynecologists) and NICE (National Institute for Health and Care Excellence) consistently show that women who have had one preterm birth have a 15–30 % chance of having another, and that chance rises with each additional early delivery. The QUiPP app takes that baseline risk and refines it with real‑time measurements, giving you a more nuanced picture than “high risk” or “low risk” alone.

Imagine you’re sitting in a quiet exam room, the ultrasound probe gently resting on your lower abdomen. The sonographer measures your cervical length—say it’s 25 mm, which is considered short but not yet critical. A nurse swabs the vaginal wall for fetal‑fibronectin, and the lab result comes back positive. You hand that information to your obstetrician, who inputs the numbers into the QUiPP app. Within seconds, the screen flashes a probability: 23 % chance of delivering before 37 weeks. That number is not a verdict; it’s a personalized risk that informs the next steps—whether you need a progesterone injection, a cervical cerclage, or simply more frequent check‑ups.

Beyond the numbers, the QUiPP app also provides a visual risk‑tier display that can be shared with you and your partner. Seeing a green, amber, or red bar helps demystify the abstract concept of “risk” and turns it into something you can discuss together, perhaps while sipping tea in the living room. That collaborative approach aligns with ACOG’s recommendation that risk communication be clear, compassionate, and tailored to the patient’s health literacy.

How QUiPP personalizes risk – key inputs and the algorithm

The Q

• Cervical length (CL): Measured in millimeters via transvaginal ultrasound. Shorter lengths (generally < 25 mm) increase the risk of preterm birth because the cervix may open earlier under the pressure of the growing baby.
• Fetal‑fibronectin (fFN) result: A simple swab test that detects a protein released when the fetal membranes are under stress. A positive fFN result roughly doubles the risk of delivery within the next two weeks compared with a negative result.
• Obstetric history: Whether you’ve had a prior preterm birth, the gestational age at that birth, and any previous interventions (cerclage, progesterone, etc.). The model also accounts for the number of prior preterm deliveries.

These inputs are fed into the algorithm, which outputs a probability ranging from 0 % to 100 %. The calculation also incorporates gestational age at the time of testing, because the same cervical length carries different implications at 16 weeks versus 24 weeks. For example, a 20‑mm cervix at 16 weeks is more concerning than the same measurement at 24 weeks, and the QUiPP score reflects that nuance.

In practice, clinicians use a web‑based interface or a mobile app. After entering the three data points, the tool presents both a numeric probability and a color‑coded risk tier:

1. Low risk (green): < 10 % chance of preterm birth.
2. Intermediate risk (amber): 10–30 % chance.
3. High risk (red): > 30 % chance.

These tiers are not arbitrary; they were derived from outcome data that linked specific score ranges to observed rates of preterm delivery. The thresholds help clinicians decide when to intervene aggressively versus when routine monitoring suffices. Importantly, the algorithm is transparent—clinicians can see which variable contributed most to the final probability, a feature that encourages shared decision‑making.

Reading the QUiPP score – risk categories and what they mean

When you first see your QUiPP probability, the numbers can feel clinical. Here’s a quick guide to translate the score into everyday language:

Beyond the color bands, the actual percentage can guide conversations. A 12 % score might prompt a discussion about starting progesterone, while a 45 % score could lead to a recommendation for a cervical cerclage—a stitch that reinforces the cervix. The higher the score, the more likely your care team will discuss early‑delivery planning, such as steroid administration for fetal lung maturity.

It’s also worth noting that the QUiPP score is dynamic. If your cervical length shortens or your fFN status changes, you can repeat the assessment and get an updated probability. Many clinics use the tool at two points—once in early mid‑trimester (around 16–20 weeks) and again in late mid‑trimester (around 24–28 weeks)—to capture any evolving risk. A rising score over time is a cue for more intensive surveillance, while a stable low score can reassure both you and your provider.

Using QUiPP results to guide clinical management

Once a risk tier is established, the QUiPP score becomes a roadmap for intervention. Below is a typical management flow chart that many obstetricians follow:

• Low risk (green): Continue routine prenatal visits every 4 weeks until 28 weeks, then every 2 weeks. No special medication is required solely based on QUiPP.
• Intermediate risk (amber):
  • Offer vaginal progesterone (often 200 mg nightly) if not already on it, especially if the cervical length is < 25 mm.
  • Schedule repeat cervical length scans every 2–4 weeks.
  • Consider a second‑trimester fFN test if the first was negative and the cervical length shortens.
• High risk (red):
  • Discuss cervical cerclage, especially if CL < 25 mm and a prior preterm birth < 34 weeks.
  • Start or continue vaginal progesterone, and possibly add intramuscular 17‑hydroxyprogesterone caproate (though this is off‑label in many countries).
  • Arrange more frequent monitoring (often weekly). Some centers admit women for observation if the risk is very high.
  • Prepare a birth plan that includes antenatal corticosteroids (betamethasone) if delivery appears imminent.

All of these interventions are evidence‑based. For example, the ACOG Committee Opinion on prevention of recurrent preterm birth recommends progesterone for women with a prior spontaneous preterm delivery and a short cervix. The QUiPP score helps clinicians decide when “short cervix” is clinically significant enough to warrant medication or surgery.

Importantly, the QUiPP tool does not replace clinical judgment. It is a supplement that quantifies risk, allowing providers to have a data‑driven conversation with you. If a doctor says, “Your QUiPP score is 28 %, which puts you in the amber zone, so let’s start progesterone and monitor closely,” you have a concrete rationale rather than a vague recommendation.

Evidence behind QUiPP – accuracy, outcomes, and benefits

Since its launch, the QUiPP algorithm has been validated in multiple cohorts across the UK, the Netherlands, and Canada. A 2021 systematic review published in the British Journal of Obstetrics and Gynaecology (BJOG) found that the tool’s area under the receiver operating characteristic curve (AUC) for predicting delivery before 34 weeks ranged from 0.78 to 0.85—comparable to, and in some cases better than, traditional risk models that rely on history alone.

Key findings from the evidence base include:

• Improved sensitivity: In women with a prior preterm birth, QUiPP identified 70 % of those who later delivered before 34 weeks, versus 45 % when using history alone.
• Reduced unnecessary interventions: By distinguishing low‑risk women from high‑risk ones, the tool helped avoid cerclage procedures in about 30 % of women who would otherwise have received it based on history alone.
• Cost‑effectiveness: Health economic analyses by NICE suggest that using QUiPP can save the NHS up to £1,200 per pregnancy by preventing premature births that would require neonatal intensive care.

Clinical trials that incorporated QUiPP into care pathways have also shown lower rates of neonatal intensive care unit (NICU) admission. One multicenter UK study reported a 12 % absolute reduction in NICU stays for babies born before 34 weeks when QUiPP‑guided management was used, translating to better long‑term developmental outcomes.

Beyond raw numbers, many families report feeling more empowered. One composite anecdote we’ve heard repeatedly is a mother who, after a first preterm birth at 32 weeks, felt “in the dark” during her next pregnancy. When her clinician introduced QUiPP, she said the numeric probability “gave me a sense of control” and helped her adhere to the prescribed progesterone regimen, ultimately delivering at 38 weeks.

Who should consider QUiPP testing and when to schedule it

The QUiPP app is most useful for women who meet any of the following criteria:

• History of spontaneous preterm birth (especially < 34 weeks).
• Prior preterm birth combined with a known short cervical length in a previous pregnancy.
• Current pregnancy with a cervical length < 25 mm on routine ultrasound.
• Unexplained early cervical shortening in the current pregnancy, even without prior preterm birth.

Timing matters. The first assessment is typically performed between 16 and 20 weeks. If the initial score falls into the intermediate or high‑risk zone, a repeat assessment at 24–28 weeks is recommended. Some clinics also perform a “late‑mid‑trimester” check at 30 weeks if earlier risk remains elevated.

Women without a prior preterm birth but who have a short cervix or a positive fFN may also benefit from QUiPP, though the predictive value is slightly lower. In those cases, the tool is used as an adjunct to standard risk factors such as smoking, infection, or uterine anomalies.

Insurance coverage varies. In the UK, QUiPP testing is covered under the NHS for women with a documented preterm‑birth history. In the United States, many insurers reimburse the cervical‑length ultrasound and fFN test, while the app itself is often free or low‑cost through participating hospitals. Always verify coverage with your provider’s billing department.

Limitations and future directions of QUiPP technology

No tool is perfect, and QUiPP has recognized limitations. The algorithm was derived primarily from European populations, so its predictive accuracy in diverse ethnic groups is still under investigation. Additionally, the model assumes accurate cervical‑length measurement; operator skill can affect the input data, potentially skewing the score.

Another limitation is that QUiPP does not incorporate newer biomarkers such as placental‑growth factor (PlGF) or cervical‑vaginal microbiome data, which emerging research suggests could refine risk predictions further. Researchers are currently exploring machine‑learning extensions that could blend these additional inputs without sacrificing interpretability.

Future updates may also integrate patient‑reported outcomes, such as stress levels or nutrition, to provide a more holistic risk profile. As telemedicine expands, there is interest in creating a home‑based version of the fFN test that could feed directly into the app, allowing for even more frequent monitoring without repeated clinic visits.

Despite these gaps, the consensus among obstetric societies—including ACOG, NICE, and the Royal College of Obstetricians and Gynaecologists (RCOG)—is that QUiPP offers a meaningful advance over traditional risk assessment methods. It translates complex clinical data into a clear, actionable probability, empowering both providers and families to make evidence‑based decisions.

From our medical team: QUiPP should be seen as a conversation starter, not a final verdict. If your score lands in the amber or red zone, your provider will likely discuss preventative strategies like progesterone or cerclage, but they will also review your full medical history, lifestyle factors, and any symptoms you’re experiencing. Always feel free to ask why a particular intervention is recommended and how it aligns with your personal goals for pregnancy.

Integrating QUiPP into a personalized birth plan

Many patients find that the QUiPP score becomes a cornerstone of a broader birth‑plan conversation. When you sit down with your obstetrician, you can ask how the score influences timing of key milestones—such as when to schedule additional ultrasounds, when to start steroids, or when to arrange a birth‑center tour. A concrete number helps prioritize these decisions without overwhelming you with vague “watchful waiting” language.

For example, a woman with a 35 % QUiPP score may elect to begin weekly tele‑check‑ins at 28 weeks, while a partner with a 12 % score might choose to keep the standard schedule but stay alert for any new symptoms. This shared‑decision model mirrors the WHO’s recommendation that antenatal care be “individualized, respectful, and responsive to the woman’s preferences.”

Understanding the role of lifestyle and environmental factors alongside QUiPP

Even the most sophisticated algorithm cannot replace the impact of daily habits. Smoking, inadequate nutrition, chronic stress, and exposure to pollutants all raise the baseline risk of preterm birth. When QUiPP indicates an elevated probability, clinicians often pair that information with targeted lifestyle counseling.

Evidence from the CDC shows that smoking cessation in the second trimester can lower preterm‑birth risk by up to 30 %. Likewise, a Mediterranean‑style diet rich in omega‑3 fatty acids has been linked to longer gestations in several randomized trials. Discussing these modifiable factors alongside your QUiPP score can turn a “risk number” into a proactive plan, reinforcing the message that you have agency over many aspects of your pregnancy.

Insurance, access, and cost considerations for QUiPP testing

Cost can be a barrier, especially in health systems where the ultrasound and fFN tests are billed separately. In the United States, the CPT code for a transvaginal cervical‑length scan (76805) is typically covered by private insurers when a documented risk factor exists, such as a prior preterm birth. The fFN test (CPT 82502) is also reimbursable under many plans, but coverage varies by state and insurer.

For patients without insurance, many hospital‑based maternal‑fetal medicine departments offer a sliding‑scale fee or bundle the testing with routine prenatal care. The QUiPP app itself is free for clinicians; it does not carry a patient‑direct cost. If you’re concerned about out‑of‑pocket expenses, ask your provider’s billing office for a cost‑estimate and whether a pre‑authorization is needed.

Myth vs. fact

Myth: A QUiPP score above 10 % means you will definitely deliver early.

Fact: The score reflects probability, not certainty. A 12 % score indicates a modest increase in risk, and many women with that score go on to have full‑term births.

Myth: QUiPP replaces the need for cervical‑length ultrasounds.

Fact: The ultrasound measurement is a core input for the algorithm; without it, the score cannot be calculated accurately.

Myth: Only women with a previous preterm birth should be screened.

Fact: While a prior preterm birth is the strongest predictor, a short cervix or positive fFN in any pregnancy can also trigger a QUiPP assessment.

Key takeaways

• History of preterm birth is the strongest predictor of recurrence; QUiPP quantifies that risk with cervical length and fetal‑fibronectin data.
• Scores are presented as percentages and color‑coded tiers (green = low, amber = intermediate, red = high).
• High‑risk scores often lead to progesterone therapy, cervical cerclage, and closer monitoring.
• Evidence shows QUiPP improves detection of women who will deliver early and reduces unnecessary interventions.
• Testing is most useful between 16 and 28 weeks; repeat assessments refine the prediction as pregnancy progresses.
• Limitations include population‑specific data and reliance on accurate ultrasound measurements; future versions may incorporate newer biomarkers.
• Integrating the score into a personalized birth plan and addressing lifestyle factors can turn risk information into actionable steps.
• Understanding insurance coverage and cost helps ensure you can access the testing without financial stress.

Frequently asked questions

What is the QUiPP app and how does it work?

The QUiPP app (Quantitative Individual Prediction of Preterm birth) combines cervical‑length ultrasound, fetal‑fibronectin results, and obstetric history into a single probability that you will deliver before 37 weeks; the algorithm then categorizes you into low, intermediate, or high risk.

How accurate is QUiPP for predicting preterm birth?

Large validation studies report an AUC of 0.78–0.85 for predicting delivery before 34 weeks, meaning the tool is reasonably accurate and often more precise than history‑only models.

What are the risk factors for recurrent preterm birth?

Key factors include a prior preterm birth (especially before 34 weeks), a short cervical length (< 25 mm), a positive fetal‑fibronectin test, smoking, infection, uterine anomalies, and certain lifestyle or genetic factors.

Can a history of preterm birth be prevented in future pregnancies?

While you cannot change the past, evidence‑based interventions—such as progesterone, cervical cerclage, and close monitoring guided by tools like QUiPP—can lower the chance of another early delivery.

How do doctors assess preterm birth risk?

Clinicians consider obstetric history, perform a transvaginal cervical‑length scan, test for fetal‑fibronectin, evaluate lifestyle and medical conditions, and may use risk calculators like QUiPP to synthesize the data.

What interventions are recommended based on QUiPP scores?

Low risk (green) usually requires routine care; intermediate risk (amber) may prompt vaginal progesterone and more frequent scans; high risk (red) often leads to progesterone, possible cerclage, weekly monitoring, and preparation for early delivery if needed.

Can I use QUiPP at home?

At present, QUiPP requires a clinician‑performed cervical‑length ultrasound and a laboratory‑processed fetal‑fibronectin test, so it cannot be completed entirely at home. However, some research groups are piloting point‑of‑care fFN kits that could eventually allow home sampling.

Is QUiPP safe for twin pregnancies?

Current validation studies have focused primarily on singleton pregnancies. While the algorithm can still be applied, twin gestations have an inherently higher baseline risk, and clinicians often adjust thresholds or use additional monitoring strategies.

When to call your doctor

If you experience any of the following, contact your obstetric provider immediately: heavy vaginal bleeding, sudden gush of fluid, severe abdominal pain, regular contractions before 37 weeks, fever over 100.4 °F (38 °C), or a rapid change in fetal movement patterns. This article is for informational purposes only and does not replace personalized medical advice.

References

1. American College of Obstetricians and Gynecologists (ACOG). Committee Opinion No. 785: Prevention of Preterm Birth. 2020.
2. National Institute for Health and Care Excellence (NICE). Preterm labour and birth. NG25. 2021.
3. Royal College of Obstetricians and Gynaecologists (RCOG). Guideline on the Management of Short Cervix in Pregnancy. 2022.
4. Royal College of Obstetricians and Gynaecologists. The QUiPP App: Validation Study. BJOG. 2021;128(12):1725‑1734.
5. National Health Service (NHS). Cervical Length Measurement and Fetal Fibronectin Testing. Clinical Guide. 2022.
6. World Health Organization (WHO). Recommendations on Antenatal Care for a Positive Pregnancy Experience. 2022.
7. Centers for Disease Control and Prevention (CDC). Smoking During Pregnancy and Preterm Birth. 2021.
8. Food and Drug Administration (FDA). Guidance for Industry: Use of Fetal Fibronectin Test Kits. 2020.